{"nctId":"NCT00770341","briefTitle":"A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)","startDateStruct":{"date":"2008-09"},"conditions":["Staphylococcal Infection"],"count":122,"armGroups":[{"label":"MK-3009 (daptomycin) 4 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Daptomycin 4 mg/kg"]},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: vancomycin"]},{"label":"MK-3009 (daptomycin) 6 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Daptomycin 6 mg/kg"]}],"interventions":[{"name":"Daptomycin 4 mg/kg","otherNames":["MK3009"]},{"name":"Comparator: vancomycin","otherNames":[]},{"name":"Daptomycin 6 mg/kg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Both Sexes, Aged 20 Years Or Older\n* Japanese Participants With Skin And Soft Tissue Infections, Septicemia, or RIE Known Or Suspected To Be Caused By MRSA\n* Written Informed Consent\n\nExclusion Criteria:\n\n* Participants With Skin and Soft Tissue infections That Can Be Treated By Surgery Alone\n* Participants With Pneumonia","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC)","description":"Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at end of treatment (EOT).\n\nMITT-MRSA (modified intent-to-treat - methicillin-resistant Staphylococcus aureus) was a subset of allocated participants with participants who were excluded for any of the following reasons: no MRSA isolated + any 1 of the following: failure to receive ≥1 dose of study drug, lack of all post-allocation primary and secondary endpoint data after ≥1 dose of study drug, no gram (+) coccus isolated at baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"EAC Assessment of Number of Participants With Clinical Success at End of Treatment (EOT).","description":"Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Microbiological Response at TOC","description":"Response = eradicated or presumed eradicated.\n\nEradicated was defined as absence of the admission pathogen in a culture obtained in the absence of potentially effective antibiotics for the pathogen.\n\nPresumed eradicated was defined as no material for culture was available due to improvement of infection, but the admission pathogen was presumed to be eradicated because the participant was deemed \"Cured\" or \"Improved\" by the investigator and the participant did not receive potentially effective antibiotics for the pathogen.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"EAC Assessment of Number of Participants With Microbiological Response at End of Treatment (EOT).","description":"Response = eradicated or presumed eradicated.\n\nEradicated was defined as absence of the admission pathogen in a culture obtained in the absence of potentially effective antibiotics for the pathogen.\n\nPresumed eradicated was defined as no material for culture was available due to improvement of infection, but the admission pathogen was presumed to be eradicated because the participant was deemed \"Cured\" or \"Improved\" by the investigator and the participant did not receive potentially effective antibiotics for the pathogen.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Study Investigators' Assessment of Clinical Response at EOT","description":"Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Study Investigators' Assessment of Clinical Response at TOC","description":"Clinical Success = Study investigator's Clinical Response confirmed by the EAC as either cured or improved at EOT.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["ALANINE AMINOTRANSFERASE INCREASED","ASPARTATE AMINOTRANSFERASE INCREASED","PYREXIA","BLOOD POTASSIUM INCREASED","C-REACTIVE PROTEIN INCREASED"]}}}